Amneal Pharmaceuticals Class A AMRX 深 沪
已收盘 12-19 16:00:00 美东时间
12.57
-0.070
-0.55%
华盛通- 最 高12.82
- 今 开12.76
- 成交量 276.23万股
- 最 低 12.53
- 昨 收 12.64
- 总市值 39.47亿
- 52周最高 12.82
- 市盈率 静 --
- 换手率 0.88%
- 52周最低 6.685
- 委 比 -51.45%
- 总股本 3.14亿
- 历史最高 24.48
- 量 比 1.23
- 振 幅 2.29%
- 历史最低 1.24
- 每 手 1
- 风险率 1.48%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 花旗上调苹果目标价升至330美元；GPCR、KYMR、MAMA、TERN、WVE等获多家机构上调目标价
今日重点评级关注：Chardan Capital：维持Senti Biosciences"买入"评级，目标价从12美元升至13美元；Guggenheim：维持Praxis Precision Medicine"买入"评级，目标价从540美元升至760美元
12-10 10:33
Amneal Receives U.S. FDA Approval for Epinephrine Injection in Single- and Multi-Dose Vials for U.S. Hospitals
Amneal Pharmaceuticals announced the FDA approval of its epinephrine injection in 1 mg/mL single-dose and multi-dose vials, a critical emergency medicine for allergic reactions and anaphylaxis. This expands the company’s injectables portfolio and provides reliable access for hospitals and care facilities.
12-09 21:01
Amneal Announces Positive Interim Phase 4 ELEVATE-PD Results With CREXONT® for Parkinson’s Disease
Amneal Pharmaceuticals announced positive interim results from its ELEVATE-PD study, showing CREXONT improved "Good On" time, reduced "Off" time, and enhanced motor symptom control in Parkinson's patients. The extended-release formulation provides longer levodopa plasma levels, offering significant real-world benefits. The study is ongoing, with long-term data expected in 2026.
12-05 13:00
Amneal Pharmaceuticals Announces FDA's Approval For Albuterol Sulfate Inhalation Aerosol
Amneal Pharmaceuticals, Inc. ("Amneal" or the "Company") (Nasdaq: AMRX) today announced that the U.S. Food and Drug Administration (FDA) has approved the Company's albuterol sulfate inhalation aerosol (90 mcg per
12-02 21:09
Amneal to Participate in Upcoming Investor Conferences
Amneal Pharmaceuticals, Inc. announced that Chirag Patel and Tasos Konidaris will participate in upcoming investor conferences. Patel and Konidaris will attend the Piper Sandler 2025 Healthcare Conference on December 3, 2025, and the J.P. Morgan 2026 Healthcare Conference on January 13, 2026. Presentations will be available via webcast on Amneal's Investor Relations website, with replays accessible for a limited time. For more details, visit thei...
12-02 13:00
Amneal Announces U.S. FDA Approval of Cyclosporine Ophthalmic Emulsion 0.05%
Amneal Pharmaceuticals received FDA approval for its 0.05% cyclosporine ophthalmic emulsion, a preservative-free, sterile treatment for dry eye disease, expected to launch Q1 2026. As the generic equivalent of Allergan's RESTASIS, the product highlights Amneal's expertise in complex ophthalmic formulations. With U.S. sales of $2.0 billion in the past year, the drug aims to increase tear production in patients with inflamed eyes. Amneal's approval...
12-01 21:01
Amneal gets FDA nod for Iohexol Injection
Amneal Pharmaceuticals (AMRX) has received approval from the U.S. FDA for its iohexol injection, which contains 300 mg of iodine per mL. This marks the introduction of the first generic version of GE ...
11-14 05:45
Amneal Pharmaceuticals shares are trading higher after the company announced it received FDA approval for its lehexol injection.
Amneal Pharmaceuticals shares are trading higher after the company announced it...
11-14 05:14
Amneal Pharmaceuticals Announces U.S. FDA Approves Its Iohexol Injection
Amneal Pharmaceuticals, Inc. ("Amneal" or the "Company") (NASDAQ:AMRX) today announced the U.S. Food and Drug Administration (FDA) has approved the Company's iohexol injection (300 mg Iodine/mL), the first generic
11-14 05:03
美股大行评级 | 苹果、亚马逊、Cloudflare、西部数据、Twilio等获十多家机构集体上调目标价；杰富瑞首予Cloudflare"持有"评级，目标价250美元
今日重点评级关注：康托·菲茨杰拉德：维持Cabaletta Bio"超配"评级，目标价从15美元升至30美元；HC Wainwright & Co.：维持Invivyd"买入"评级，目标价从5美元升至10美元
11-03 20:20
